Blocking of p53-snail binding, promoted by oncogenic K-Ras, recovers p53 expression and function

Neoplasia

Volumn 11, Issue 1, 2009, Pages 22-31

  Lee, Sun Hye ^a   Lee, Su Jin ^a   Yeon, Sang Jung ^a   Xu, Yongbin ^a   Ho, Sung Kang ^a   Ha, Nam Chul ^a   Park, Bum Joon ^a  

^a Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; K RAS PROTEIN; MUTANT PROTEIN; PROTEIN P53; QUERCETIN; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SNAIL;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MUTANT; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TRANSCRIPTION INITIATION; WILD TYPE;

EID: 58249119433     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81006     Document Type: Article

References (42)

1. Downward J (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3, 11-22.
2. Weinberg RA (2006). The Biology of Cancer. 1st ed. Gerald Science.
3. Downward J (1998). Ras signalling and apoptosis. Curr Opin Genet Dev 8, 49-54.
4. Deramaudt T and Rustgi AK (2005). Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 1756, 97-101.
5. Yaswen P and Campisi J (2007). Oncogene-induced senescence pathways weave an intricate tapestry. Cell 128, 233-234.
6. INK4a. Cell 88, 593-602.
7. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, and Jacks T (2007). Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665.
8. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, and Lowe SW (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660.
9. Leslie A, Pratt NR, Gillespie K, Sales M, Kernohan NM, Smith G, Wolf CR, Carey FA, and Steele RJ (2003). Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. Cancer Res 63, 4656-4661.
10. Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP, Konishi Y, Gallmeier E, Bachman KE, and Park BH (2007). Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res 67, 8460-8467.
11. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Campuzano V, and Barbacid M (2003). Tumor induction by an endogenous K-Ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120.
12. G12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387.
13. Brooks CL and Gu W (2006). p53 ubiquitination, Mdm2 and beyond. Mol Cell 21, 307-315.
14. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, and Vogelstein B (1993). p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53, 2231-2234.
15. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, and Healey JH (1993). MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53, 16-18.
16. Waber PG, Chen J, and Nisen PD (1993). Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 53, 6028-6030.
17. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, et al. (1998). The alternative product from the human CDKN2A locus, p14(ARF)., participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17, 5001-5014.
18. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, and Bar-Sagi D (1999). Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1, 20-26.
19. ARF. Cell 103, 321-330.
20. Tolbert D, Lu X, Yin C, Tantama M, and Van Dyke T (2002). p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Mol Cell Biol 22, 370-377.
21. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, and Herman JG (2000). Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60, 129-133.
22. Sherr CJ (2006). Divorcing ARF and p53, an unsettled case. Nat Rev Cancer 6, 663-673.
23. Peinado H, Olmeda D, and Cano A (2007). Snail, Zeb and bHLH factors in tumour progression, an alliance against the epithelial phenotype? Nat Rev Cancer 7, 415-428.
24. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, and Chi SG (2003). Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 22, 4314-4332.
25. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, and Hung MC (2004). Dual regulation of Snail by GSK-3b-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6, 931-940.
26. Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK, and Donner DB (2005). Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 280, 25953-25959.
27. Kajita M, McClinic KN, and Wade PA (2004). Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol 24, 7559-7566.
28. Brès V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, Tréand C, Emiliani S, Peloponese JM, Jeang KT, Coux O, et al. (2003). A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat Cell Biol 5, 754-761.
29. Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T, and Schmitt CA (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665.
30. Peeper DS, Shvarts A, Brummelkamp T, Douma S, Koh EY, Daley GQ, and Bernards R (2002). A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol 4, 148-153.
31. Park BJ, Oh YS, Park SY, Choi SJ, Rudolph C, Schlegelberger B, and Kim S (2006). AIMP3 haploinsufficiency disrupts oncogene-induced p53 activation and genomic stability. Cancer Res 66, 6913-6918.
32. Tang HJ, Qian D, Sondak VK, Stachura S, and Lin J (2004). A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin. Br J Cancer 90, 1285-1292.
33. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
34. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, and Nieto MA (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2, 76-83.
35. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J, and García De Herreros A (2000). The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2, 84-89.
36. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, and Chodosh LA (2005). The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8, 197-209.
37. Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP, Kanadaswam C, and Lee MT (2002). Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res 22, 1615-1627.
38. Nöthlings U, Murphy SP, Wilkens LR, Henderson BE, and Kolonel LN (2007). Flavonols and pancreatic cancer risk, the multiethnic cohort study. Am J Epidemiol 166, 924-931.
39. Halaschek-Weiner J, Wacheck V, Kloog Y, and Jansen B (2004). Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2; two mechanisms that cooperatively increase p53 function in colon cancer cells. Cell Signal 16, 1319-1327.
40. De Craene B and Berx G (2006). Snail in the frame of malignant tumor recurrence. Breast Cancer Res 8, 105.
41. Park BJ, Kang JW, Lee SW, Choi SJ, Shin YK, Ahn YH, Choi YH, Choi D, Lee KS, and Kim S (2005). The haploinsufficient tumor suppressor p18 upregulates p53 via interactions with ATM/ATR. Cell 120, 209-221.
42. Hurley PJ and Bunz F (2007). ATM and ATR, components of an integrated circuit. Cell Cycle 6, 414-417.